OmniActive Health Technologies (OmniActive) today announced results from two newly published, peer-reviewed clinical studies in Advances in Therapy demonstrating the bioavailability and efficacy of Zenroot.
Zenroot is the brand's proprietary root-only ashwagandha (Withania somnifera) extract standardised to 1.5% withanolides.
Both studies were conducted using adults between 18 and 55 years of age and used a daily dose of 125mg.
The first study, a randomised, double-blind, single-dose, cross-over, comparative, oral bioavailability study, Zenroot demonstrated:
- More than two times higher absorption than a 600mg reference product and more than one and one-third times higher absorption than a 500 mg reference product
- The Zenroot group had significantly higher plasma withanolides content at multiple time points as compared to the reference products
- It was well-tolerated under fasting conditions.
“To our knowledge, this is the most comprehensive bioavailability study of ashwagandha extract in human volunteers,” said Abhijeet Morde, Divisional VP of Clinical Research at OmniActive.
“By measuring individual withanolides (withanoside IV, withanolide A, 12-deoxywithastramonolide and withaferin A) as per FDA guidance, we’ve set a new benchmark for ingredient transparency and performance, data that empowers brands to select clinically supported solutions aligned with consumer health goals."
The second study, a 12-week, randomised, double-blind, placebo-controlled trial, using adults with mild to moderate stress, daily supplementation with Zenroot led to:
- Significant decrease in stress in less than 30 days as measured by the Perceived Stress Scale and Mindfield eSense Skin Response
- Reduced feelings of occasional anxiety
- Fewer mood fluctuations in response to everyday stressors, starting at day 56
- Statistically significant improvements in sleep quality by day 28 versus baseline and placebo.
“The ashwagandha category is booming as consumers look for clean label, non-pharmacological solutions to support mood, sleep and stress management,” said Keya Shah, Category Manager at OmniActive.
“Zenroot’s studies reinforce its ability to deliver a clinically validated, high-performance botanical ingredient that meets these demands in a crowded, fast-growing market.”
According to Future Market Insights, the global ashwagandha extract market is projected to grow from $815.7m in 2025 to $1.79bn by 2035.
The momentum is partly fuelled by younger US. consumers embracing adaptogens in new functional formats, while Europe is rapidly seeing growth in sports nutrition and clean-label wellness categories.
Shah added: “Just months after its launch, Zenroot has been well-received as a root-only ashwagandha, an important distinction for product quality, safety, efficacy and regulatory compliance in certain regions.”